+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sepsis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 5012596
  • Report
  • April 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Adrenomed AG
  • Allergan, Inc.
  • Asahi Kasei Corporation
  • ENDACEA, INC.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Inc
  • MORE
The Sepsis Therapeutics market is projected to grow with a CAGR of 7.6% over the forecast period. The major factor attributing to the growth of the market is the rising incidence of sepsis globally. According to the World Health Organization, it is estimated to affect more than 30 million people worldwide every year, potentially leading to 6 million deaths. The burden of sepsis is most likely highest in low- and middle-income countries. Furthermore, increasing research and development programs and funding is boosting the market growth.

However, the lack of initial diagnostic test for identifying sepsis conditions and lack of awareness of the treatment is constraining the market.

Key Market Trends

Cephalosporins Dominate the Sepsis Therapeutics Market

The dominant share of the segment is attributed to the vast usage of the drug class, individually or in combination with the other drugs.

Cephalosporins are divided into first, second, third, and fourth generation. First-generation cephalosporins have greater activity against gram-positive bacteria, and succeeding generations have increased activity against gram-negative bacteria and decreased activity against gram-positive bacteria.

Apart from the advantages and broad spectrum activity of cephalosporins, the increasing incidence of sepsis is boosting the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast PeriodNorth America is expected to dominate the overall sepsis therapeutics market, throughout the forecast period. The largest share is mainly due to presence of larger patient pool and increasing geriatric population. Furthermore, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the other factors boosting the market in this region. In North America region, the United States holds the largest market share due to the factors such as increasing number of geriatric populations, along with a growing number of patient pool in the country. According to Sepsis.org., more than 1.7 million people in the country are diagnosed with sepsis each year, one every 20 seconds and the incidence is rising 8% every year and the cost of hospitalization in the U.S. consuming more than USD 27 billion each year. As per the statistics the large patient pool and high disposable income propels the market growth in the region.

North America is expected to dominate the overall sepsis therapeutics market, throughout the forecast period. The largest share is mainly due to the presence of larger patient pool and increasing geriatric population. Furthermore, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the other factors boosting the market in this region. In North America region, the United States holds the largest market share due to the factors such as increasing number of geriatric populations, along with a growing number of patient pool in the country. According to Sepsis.org., more than 1.7 million people in the country are diagnosed with sepsis each year, one every 20 seconds and the incidence is rising 8% every year and the cost of hospitalization in the U.S. consuming more than USD 27 billion each year. As per the statistics the large patient pool and high disposable income propels the market growth in the region.

Competitive Landscape

The Sepsis Therapeutics market moderately competetive. A few of the crucial approaches followed by players functioning arket were, product advancement, invention, acquisitions and mergers. Some of the companies which are currently domianting the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline Inc, Mylan N.V. , Allergan, Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adrenomed AG
  • Allergan, Inc.
  • Asahi Kasei Corporation
  • ENDACEA, INC.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Inc
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Sepsis
4.2.2 Increasing Geraiatric Poulation
4.2.3 Rise in the Number of Pipeline Products and Upsurge in Research & Development Expenditures
4.3 Market Restraints
4.3.1 Lack of Initial Diagnostic Test for identifying Sepsis Conditions and Lack of Awareness
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Aminoglycosides
5.1.2 Cephalosporin
5.1.3 Glycopeptide Antibiotics
5.1.4 Others
5.2 By Route of Administration
5.2.1 Intravenous
5.2.2 Oral
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd
6.1.2 Pfizer Inc.
6.1.3 GlaxoSmithKline Inc
6.1.4 Mylan N.V.
6.1.5 Allergan, Inc.
6.1.6 Asahi Kasei Corporation
6.1.7 RegeneRx
6.1.8 INOTREM S.A
6.1.9 ENDACEA, INC.
6.1.10 Adrenomed AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • GlaxoSmithKline Inc
  • Mylan N.V.
  • Allergan, Inc.
  • Asahi Kasei Corporation
  • RegeneRx
  • INOTREM S.A
  • ENDACEA, INC.
  • Adrenomed AG
Note: Product cover images may vary from those shown
Adroll
adroll